Ten month gap between AstraZeneca doses sees highest antibody boost: Oxford study
The Hindu
Study also reported reduced common adverse events after the second dose
Two doses of the AstraZeneca vaccine administered 44-45 weeks apart generated nearly four times the level of antibodies than when the doses were given 8-12 weeks apart, says a report by the Oxford Vaccine Group, the developers of the vaccine, on Monday. Antibody levels remained elevated for nearly a year and a third booster dose of the vaccine, given to a subset of volunteers, also significantly boosted antibody levels to twice that after a second dose. “A single dose of ChAdOx1 nCoV-19, with a second dose given after a prolonged period, may, therefore, be an effective strategy when vaccine supplies are scarce in the short term. A third dose results in a further increase in immune responses, including greater neutralisation of variant SARS-CoV-2 viruses, and could be used to increase vaccine efficacy against variants in vulnerable populations,” the authors report in a pre-print publication. This means the study is yet to peer-reviewed. A group of vaccine volunteers who got their second dose 15-25 weeks after the first, saw average antibody levels at nearly twice those in the 8-12 week interval, suggesting that lengthening the duration between doses appeared to be boosting antibody count.More Related News

Former CM B.S. Yediyurappa had challenged the first information report registered on March 14, 2024, on the alleged incident that occurred on February 2, 2024, the chargesheet filed by the Criminal Investigation Department (CID), and the February 28, 2025, order of taking cognisance of offences afresh by the trial court.